

Efficacy of B-Cell Targeted Therapy With Rituximab in Severe Graves' Orbitopathy: A Randomized Controlled S

Journal of Clinical Endocrinology and Metabolism

100, 422-431

DOI: [10.1210/jc.2014-3014](https://doi.org/10.1210/jc.2014-3014)

Citation Report

#	ARTICLE	IF	CITATIONS
2	Current trends in the management of thyroid eye disease. <i>Current Opinion in Ophthalmology</i> , 2015, 26, 484-490.	1.3	29
3	Graves's™ Ophthalmopathy: VISA versus EUGOGO Classification, Assessment, and Management. <i>Journal of Ophthalmology</i> , 2015, 2015, 1-16.	0.6	139
4	An Overview of Organ-Specific Autoimmune Diseases Including Immunotherapy. <i>Immunological Investigations</i> , 2015, 44, 803-816.	1.0	31
5	Effects of treatment modalities for Graves's™ hyperthyroidism on Graves's™ orbitopathy: a 2015 Italian Society of Endocrinology Consensus Statement. <i>Journal of Endocrinological Investigation</i> , 2015, 38, 481-487.	1.8	44
6	Medical Treatment of Graves's™ Orbitopathy. <i>Hormone and Metabolic Research</i> , 2015, 47, 779-788.	0.7	47
7	Current Insights into the Pathogenesis of Graves's™ Ophthalmopathy. <i>Hormone and Metabolic Research</i> , 2015, 47, 773-778.	0.7	161
8	Modeling Graves's™ Orbitopathy in Experimental Graves's™ Disease. <i>Hormone and Metabolic Research</i> , 2015, 47, 797-803.	0.7	42
9	Future Prospects for the Treatment of Graves's™ Hyperthyroidism and Eye Disease. <i>Hormone and Metabolic Research</i> , 2015, 47, 789-796.	0.7	33
10	Future Research in Graves' Orbitopathy: From Priority Setting to Trial Design Through Patient and Public Involvement. <i>Thyroid</i> , 2015, 25, 1181-1184.	2.4	8
11	Current Trends in the Management of Thyroid Ophthalmopathy. <i>Hanyang Medical Reviews</i> , 2016, 36, 186.	0.4	3
12	Resolution of Graves's™ disease after renal transplantation. <i>Pediatric Transplantation</i> , 2016, 20, 590-593.	0.5	1
13	Graves's™ disease syndrome: a need for unified therapy. <i>Journal of Translational Internal Medicine</i> , 2016, 4, 61-63.	1.0	1
14	Critical Differences between Induced and Spontaneous Mouse Models of Graves's™ Disease with Implications for Antigen-Specific Immunotherapy in Humans. <i>Journal of Immunology</i> , 2016, 197, 4560-4568.	0.4	17
18	Prospective, systematically recorded mycophenolate safety data in Graves's™ orbitopathy. <i>Journal of Endocrinological Investigation</i> , 2016, 39, 687-694.	1.8	17
19	Rationale for therapeutic targeting insulin-like growth factor-1 receptor and bone marrow-derived fibrocytes in thyroid-associated ophthalmopathy. <i>Expert Review of Ophthalmology</i> , 2016, 11, 77-79.	0.3	5
20	The 2016 European Thyroid Association/European Group on Graves' Orbitopathy Guidelines for the Management of Graves' Orbitopathy. <i>European Thyroid Journal</i> , 2016, 5, 9-26.	1.2	738
21	Clinical efficacy of combined rituximab treatment in a woman with severe Graves' ophthalmopathy. <i>Experimental and Therapeutic Medicine</i> , 2016, 12, 1093-1096.	0.8	3
23	Current trends in antithyroid drug treatment of Graves's™ disease. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 2005-2017.	0.9	17

#	ARTICLE	IF	CITATIONS
24	Thyroid eye disease- an update. Expert Review of Ophthalmology, 2016, 11, 273-284.	0.3	14
25	Gravesâ€™ Disease. New England Journal of Medicine, 2016, 375, 1552-1565.	13.9	847
26	THERAPY OF ENDOCRINE DISEASE: Endocrine dilemma: management of Gravesâ€™ orbitopathy. European Journal of Endocrinology, 2016, 175, R117-R133.	1.9	31
27	An Animal Model of Gravesâ€™ Orbitopathy. Essentials in Ophthalmology, 2016, , 117-126.	0.0	0
28	Reversal of Pathological Features of Graves' Orbitopathy by Activation of Forkhead Transcription Factors, FOXOs. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 114-122.	1.8	26
29	Advances in the pharmacological treatment of Gravesâ€™ orbitopathy. Expert Review of Clinical Pharmacology, 2016, 9, 981-989.	1.3	22
30	Novel Therapies for Thyroid Autoimmune Diseases. Expert Review of Clinical Pharmacology, 2016, 9, 853-861.	1.3	25
31	Molecular diagnosis: Implications for ophthalmology. Progress in Retinal and Eye Research, 2016, 50, 25-33.	7.3	7
32	Pathogenesis of thyroid eye disease: review and update on molecular mechanisms. British Journal of Ophthalmology, 2016, 100, 142-150.	2.1	151
33	Advances in treatment of active, moderate-to-severe Graves' ophthalmopathy. Lancet Diabetes and Endocrinology,the, 2017, 5, 134-142.	5.5	111
34	Orbital fibroblasts of Graves' orbitopathy stimulated with proinflammatory cytokines promote B cell survival by secreting BAFF. Molecular and Cellular Endocrinology, 2017, 446, 1-11.	1.6	15
35	The Efficacy of Rituximab Combined with ¹³¹I for Ophthalmic Outcomes of Graves' Ophthalmopathy Patients. Pharmacology, 2017, 99, 144-152.	0.9	10
36	Treatment by rituximab on six Grave's ophthalmopathies resistant to corticosteroids. Annales D'Endocrinologie, 2017, 78, 20-26.	0.6	7
37	Does early response to intravenous glucocorticoids predict the final outcome in patients with moderate-to-severe and active Gravesâ€™ orbitopathy?. Journal of Endocrinological Investigation, 2017, 40, 547-553.	1.8	57
38	Teprotumumab for Thyroid-Associated Ophthalmopathy. New England Journal of Medicine, 2017, 376, 1748-1761.	13.9	480
39	Teprotumumab: a new avenue for the management of moderate-to-severe and active Gravesâ€™ orbitopathy?. Journal of Endocrinological Investigation, 2017, 40, 885-887.	1.8	17
40	Molecularly targeted agents in oculoplastic surgery. Current Opinion in Ophthalmology, 2017, 28, 485-492.	1.3	9
41	Cyclic Peptides for Effective Treatment in a Long-Term Model of Graves Disease and Orbitopathy in Female Mice. Endocrinology, 2017, 158, 2376-2390.	1.4	26

#	ARTICLE	IF	CITATIONS
42	Update on the use of immunoglobulin in human disease: A review of evidence. Journal of Allergy and Clinical Immunology, 2017, 139, S1-S46.	1.5	454
43	Combination Therapy of Intravenous Steroids and Orbital Irradiation is More Effective Than Intravenous Steroids Alone in Patients with Graves' Orbitopathy. Hormone and Metabolic Research, 2017, 49, 739-747.	0.7	34
44	Teprotumumab, an Antibody that Blocks the IGF-I Receptor, Causes Dramatic Improvement in Graves' Orbitopathy. Clinical Thyroidology, 2017, 29, 261-263.	0.0	1
45	Tocilizumab as a steroid sparing agent for the treatment of Graves' orbitopathy. American Journal of Ophthalmology Case Reports, 2017, 7, 146-148.	0.4	28
46	Risk factors predisposing to the development of hypogammaglobulinemia and infections post-Rituximab. International Reviews of Immunology, 2017, 36, 352-359.	1.5	84
47	Update on Graves disease. Current Opinion in Ophthalmology, 2017, 28, 505-513.	1.3	31
49	Novel Immunomodulatory Treatment Modalities. , 2017, , 177-192.		0
50	Protocols of Non-Surgical Therapies. , 2017, , 330-337.		2
51	MANAGEMENT OF ENDOCRINE DISEASE: Rituximab therapy for Graves' orbitopathy – lessons from randomized control trials. European Journal of Endocrinology, 2017, 176, R101-R109.	1.9	83
52	MANAGEMENT OF ENDOCRINE DISEASE: Regenerative therapies in autoimmune Addison's disease. European Journal of Endocrinology, 2017, 176, R123-R135.	1.9	30
53	Thyroid eye disease: a review. Australasian journal of optometry, The, 2017, 100, 20-25.	0.6	82
54	Review of Mouse Models of Graves' Disease and Orbitopathy – Novel Treatment by Induction of Tolerance. Clinical Reviews in Allergy and Immunology, 2017, 52, 182-193.	2.9	25
55	Mechanisms of Autoantibody-Induced Pathology. Frontiers in Immunology, 2017, 8, 603.	2.2	377
56	Thyroid Autoantibodies Display both –Original Antigenic Sin– and Epitope Spreading. Frontiers in Immunology, 2017, 8, 1845.	2.2	17
57	Thyroid Autoimmunity and Function after Treatment with Biological Antirheumatic Agents in Rheumatoid Arthritis. Frontiers in Endocrinology, 2017, 8, 179.	1.5	20
58	Rituximab therapy in pemphigus and other autoantibody-mediated diseases. F1000Research, 2017, 6, 83.	0.8	23
59	Recent advances in understanding autoimmune thyroid disease: the tallest tree in the forest of polyautoimmunity. F1000Research, 2017, 6, 1776.	0.8	87
60	Challenges and developments in both surgical and non-surgical treatments for thyroid eye disease. Expert Review of Ophthalmology, 2018, 13, 105-112.	0.3	0

#	ARTICLE	IF	CITATIONS
61	Efficacy and Safety of Rituximab for the Treatment of Graves' Orbitopathy: A Meta-analysis of Randomized Controlled Trials. <i>Pharmacotherapy</i> , 2018, 38, 503-510.	1.2	27
62	Combined immunosuppression and radiotherapy in thyroid eye disease (CIRTED): a multicentre, 2-factorial, double-blind, randomised controlled trial. <i>Lancet Diabetes and Endocrinology</i> , 2018, 6, 299-309.	5.5	68
63	Graves' disease. Time to move on. <i>Archives of Disease in Childhood</i> , 2018, 103, archdischild-2017-314486.	1.0	3
64	Adding the Immunosuppressant Mycophenolate Mofetil to Medium-Dose Infusions of Methylprednisolone Improves the Treatment of Graves' Orbitopathy. <i>Clinical Thyroidology</i> , 2018, 30, 10-14.	0.0	5
65	40 YEARS OF IGF1: IGF1 receptor and thyroid-associated ophthalmopathy. <i>Journal of Molecular Endocrinology</i> , 2018, 61, T29-T43.	1.1	50
66	Chemotherapy-induced exacerbations of thyroid orbitopathy in a patient with B-cell lymphoma. <i>Orbit</i> , 2018, 37, 299-302.	0.5	2
67	Extraocular muscle repositioning as the last therapeutic option for a patient with a severe course of Graves' Ophthalmopathy: a case report. <i>BMC Ophthalmology</i> , 2018, 18, 56.	0.6	1
68	Thyroid Orbitopathy. <i>International Ophthalmology Clinics</i> , 2018, 58, 137-179.	0.3	31
69	IgG4-related orbital disease masquerading as thyroid eye disease, vice versa, or both?. <i>Orbit</i> , 2018, 37, 239-242.	0.5	5
70	Comparative Efficacy of Medical Treatments for Thyroid Eye Disease: A Network Meta-Analysis. <i>Journal of Ophthalmology</i> , 2018, 2018, 1-10.	0.6	5
71	Thyroid eye disease. <i>Current Opinion in Ophthalmology</i> , 2018, 29, 528-534.	1.3	33
72	New advances in understanding thyroid-associated ophthalmopathy and the potential role for insulin-like growth factor-I receptor. <i>F1000Research</i> , 2018, 7, 134.	0.8	15
73	Corticosteroids for Graves' Ophthalmopathy: Systematic Review and Meta-Analysis. <i>BioMed Research International</i> , 2018, 2018, 1-9.	0.9	19
74	Combined immunosuppressants and less steroids in active graves' orbitopathy?. <i>Clinical Endocrinology</i> , 2018, 90, 525-527.	1.2	3
75	Efficacy and Safety of Immunosuppressive Agents for Thyroid Eye Disease. <i>Ophthalmic Plastic and Reconstructive Surgery</i> , 2018, 34, S56-S59.	0.4	22
76	Current and Future Treatments for Graves' Disease and Graves' Ophthalmopathy. <i>Hormone and Metabolic Research</i> , 2018, 50, 871-886.	0.7	27
77	Reflections on Thyroid Autoimmunity: A Personal Overview from the Past into the Future. <i>Hormone and Metabolic Research</i> , 2018, 50, 840-852.	0.7	17
78	The role of tocilizumab in the treatment of inflammatory diseases of the eye and orbit: A useful alternative. <i>Journal Francais D'Ophthalmologie</i> , 2018, 41, 759-766.	0.2	13

#	ARTICLE	IF	CITATIONS
79	Is there potential for the approval of monoclonal antibodies to treat thyroid-associated ophthalmopathy?. Expert Opinion on Orphan Drugs, 2018, 6, 593-595.	0.5	7
80	Gravesâ€™ orbitopathy: Diagnosis and treatment. Annales D'Endocrinologie, 2018, 79, 656-664.	0.6	19
81	Treatment of adult Gravesâ€™ disease. Annales D'Endocrinologie, 2018, 79, 618-635.	0.6	19
82	The effect of oral statin therapy on strabismus in patients with thyroid eye disease. Journal of AAPOS, 2018, 22, 340-343.	0.2	8
83	Treatment of Concurrent Thrombotic Thrombocytopenic Purpura and Gravesâ€™ Disease: A Report on Two Cases. Case Reports in Endocrinology, 2018, 2018, 1-4.	0.2	7
84	Orbital Decompression for Thyroid-Related Orbitopathy During the Quiescent Phase. Ophthalmic Plastic and Reconstructive Surgery, 2018, 34, S90-S97.	0.4	16
85	Medical and Surgical Options in Thyroid Eye Disease. , 2018, , 493-502.		0
86	Enduring remission of active and sight-threatening Gravesâ€™ orbitopathy with rituximab: report of two cases. Endocrine Journal, 2018, 65, 963-967.	0.7	2
87	Gravesâ€™ Orbitopathy. , 2018, , 711-718.		0
88	Efficacy of Tocilizumab in Patients With Moderate-to-Severe Corticosteroid-Resistant Graves Orbitopathy: A Randomized Clinical Trial. American Journal of Ophthalmology, 2018, 195, 181-190.	1.7	177
89	Thyroid Autoimmunity. , 2018, , 636-650.		0
90	Antigen-specific therapy of Graves acute disease and orbitopathy by induction of tolerance. Frontiers in Bioscience - Landmark, 2018, 23, 2044-2052.	3.0	5
91	Does rituximab improve clinical outcomes of patients with thyroid-associated ophthalmopathy? A systematic review and meta-analysis. BMC Ophthalmology, 2018, 18, 46.	0.6	18
92	Gravesâ€™ Ophthalmopathy. Endocrinology, 2018, , 451-488.	0.1	0
93	Treatment of Gravesâ€™ Disease. Endocrinology, 2018, , 489-511.	0.1	0
94	Challenges in Orphan Drug Development: Identification of Effective Therapy for Thyroid-Associated Ophthalmopathy. Annual Review of Pharmacology and Toxicology, 2019, 59, 129-148.	4.2	25
95	A New Era in the Treatment of Thyroid Eye Disease. American Journal of Ophthalmology, 2019, 208, 281-288.	1.7	46
96	Intravenous glucocorticoids therapy in the treatment of Gravesâ€™ ophthalmopathy: a systematic review and Meta-analysis. International Journal of Ophthalmology, 2019, 12, 1177-1186.	0.5	14

#	ARTICLE	IF	CITATIONS
97	Zirconium-89-labelled rituximab PET-CT in orbital inflammatory disease. <i>EJNMMI Research</i> , 2019, 9, 69.	1.1	19
98	Fingolimod Improves the Outcome of Experimental Graves' Disease and Associated Orbitopathy by Modulating the Autoimmune Response to the Thyroid-Stimulating Hormone Receptor. <i>Thyroid</i> , 2019, 29, 1286-1301.	2.4	14
99	Systematic Review of Safety and Efficacy of Rituximab in Treating Immune-Mediated Disorders. <i>Frontiers in Immunology</i> , 2019, 10, 1990.	2.2	133
100	Current and Emerging Treatment Strategies for Graves's™ Orbitopathy. <i>Drugs</i> , 2019, 79, 109-124.	4.9	56
101	Insulin-like Growth Factor-I Receptor and Thyroid-Associated Ophthalmopathy. <i>Endocrine Reviews</i> , 2019, 40, 236-267.	8.9	117
102	Adjuvant rituximab, a potential treatment for the young patient with Graves's™ hyperthyroidism (RiGD): study protocol for a single-arm, single-stage, phase II trial. <i>BMJ Open</i> , 2019, 9, e024705.	0.8	7
103	Active Moderate-to-Severe Graves' Orbitopathy in a Patient With Type 2 Diabetes Mellitus and Vascular Complications. <i>Frontiers in Endocrinology</i> , 2018, 9, 810.	1.5	3
104	Clinical Experience with Rituximab and Intravenous Immunoglobulin for Pretibial Myxedema: A Case Series. <i>Thyroid</i> , 2019, 29, 692-699.	2.4	12
105	Early low-dose rituximab for active thyroid eye disease: An effective and well-tolerated treatment. <i>Clinical Endocrinology</i> , 2019, 91, 179-186.	1.2	25
106	Development of a core outcome set for amblyopia, strabismus and ocular motility disorders: a review to identify outcome measures. <i>BMC Ophthalmology</i> , 2019, 19, 47.	0.6	10
107	Management of thyroid eye disease-related strabismus. <i>Journal of Current Ophthalmology</i> , 2019, 32, 1-13.	0.3	5
108	Immunological Aspects of Graves's™ Ophthalmopathy. <i>BioMed Research International</i> , 2019, 2019, 1-12.	0.9	63
109	Immunotherapies for thyroid eye disease. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2019, 26, 250-255.	1.2	18
110	<p>Thyroid Eye Disease: How A Novel Therapy May Change The Treatment Paradigm</p>. <i>Therapeutics and Clinical Risk Management</i> , 2019, Volume 15, 1305-1318.	0.9	17
111	Triamcinolone for the Treatment of Graves Ophthalmopathy Tested With Short Tau Inversion Recovery Magnetic Resonance. <i>Ophthalmic Plastic and Reconstructive Surgery</i> , 2019, 35, 22-24.	0.4	4
113	Cambridge Ophthalmological Symposium 2018: introduction and reflections on the day. <i>Eye</i> , 2019, 33, 169-173.	1.1	0
115	6 Pathogenesis of Thyroid Eye Disease. , 2019, , .		0
116	Graves's™ Ophthalmopathy. , 2019, , 323-337.		1

#	ARTICLE	IF	CITATIONS
118	Low-Dose Rituximab for Active Moderate to Severe Gravesâ€™ Orbitopathy Resistant to Conventional Treatment. <i>Ocular Immunology and Inflammation</i> , 2019, 27, 844-850.	1.0	17
119	Tocilizumab for the Management of Corticosteroid-Resistant Mild to Severe Gravesâ€™ Ophthalmopathy, a Report of Three Cases. <i>Ocular Immunology and Inflammation</i> , 2020, 28, 281-284.	1.0	15
120	The effects of Rituximab on Gravesâ€™ orbitopathy: A retrospective study of 14 patients. <i>European Journal of Ophthalmology</i> , 2020, 30, 1008-1013.	0.7	19
121	Immunohistochemical analysis of human orbital tissue in Gravesâ€™ orbitopathy. <i>Journal of Endocrinological Investigation</i> , 2020, 43, 123-137.	1.8	35
122	Treatment strategies for Gravesâ€™ ophthalmopathy: a network meta-analysis. <i>British Journal of Ophthalmology</i> , 2020, 104, 551-556.	2.1	12
123	Thyroid eye disease: current and potential medical management. <i>International Ophthalmology</i> , 2020, 40, 1035-1048.	0.6	8
124	New insights into the pathogenesis and nonsurgical management of Graves orbitopathy. <i>Nature Reviews Endocrinology</i> , 2020, 16, 104-116.	4.3	155
125	Current Understanding of the Progression and Management of Thyroid Associated Orbitopathy: A Systematic Review. <i>Ophthalmology and Therapy</i> , 2020, 9, 21-33.	1.0	37
126	Advances in the Orbital Decompressive Surgery for the Treatment of Graves' Ophthalmopathy. , 2020, , 247-258.		0
127	Novel therapies for thyroid autoimmune diseases: An update. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2020, 34, 101366.	2.2	26
128	Orbital disease in neuro-ophthalmology. <i>Current Opinion in Ophthalmology</i> , 2020, 31, 469-474.	1.3	1
129	Medical and surgical treatment of thyroid eye disease. <i>Internal Medicine Journal</i> , 2022, 52, 14-20.	0.5	7
130	Proposal for Standardization of Primary and Secondary Outcomes in Patients with Active, Moderate-to-Severe Gravesâ€™ Orbitopathy. <i>European Thyroid Journal</i> , 2020, 9, 3-16.	1.2	23
131	Advances in steroid sparing medical management of active thyroid eye disease. <i>Seminars in Ophthalmology</i> , 2020, 35, 216-223.	0.8	1
132	Comparison of efficacy and safety of parenteral versus parenteral and oral glucocorticoid therapy in Gravesâ€™ orbitopathy. <i>International Journal of Clinical Practice</i> , 2020, 74, e13608.	0.8	8
133	Teprotumumab Treatment for Thyroid-Associated Ophthalmopathy. <i>European Thyroid Journal</i> , 2020, 9, 31-39.	1.2	5
134	Thyroid-associated ophthalmopathy: Emergence of teprotumumab as a promising medical therapy. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2020, 34, 101383.	2.2	10
135	Use of Rituximab After Orbital Decompression Surgery in Two Graveâ€™s Ophthalmopathy Patients Progressing to Optic Neuropathy. <i>Frontiers in Endocrinology</i> , 2020, 11, 583565.	1.5	4

#	ARTICLE	IF	CITATIONS
136	Teprotumumab for the treatment of thyroid eye disease. Expert Review of Clinical Immunology, 2020, 16, 739-743.	1.3	3
138	Tocilizumab versus Rituximab in Patients with Moderate to Severe Steroid-resistant Gravesâ€™ Orbitopathy. Ocular Immunology and Inflammation, 2022, 30, 500-505.	1.0	9
139	Anti-IL-6 Receptor Tocilizumab in Refractory Gravesâ€™ Orbitopathy: National Multicenter Observational Study of 48 Patients. Journal of Clinical Medicine, 2020, 9, 2816.	1.0	36
140	Management of Graves Thyroidal and Extrathyroidal Disease: An Update. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 3704-3720.	1.8	107
141	New Therapeutic Horizons for Gravesâ€™ Hyperthyroidism. Endocrine Reviews, 2020, 41, 873-884.	8.9	56
142	Novel Approaches for Immunosuppression in Gravesâ€™ Hyperthyroidism and Associated Orbitopathy. European Thyroid Journal, 2020, 9, 17-30.	1.2	18
143	Modulating TSH Receptor Signaling for Therapeutic Benefit. European Thyroid Journal, 2020, 9, 66-77.	1.2	13
144	Teprotumumab: a novel therapeutic monoclonal antibody for thyroid-associated ophthalmopathy. Expert Opinion on Investigational Drugs, 2020, 29, 645-649.	1.9	13
145	Efficacy of rituximab in patients with Gravesâ€™ orbitopathy: a retrospective multicenter nationwide study. Graefe's Archive for Clinical and Experimental Ophthalmology, 2020, 258, 2013-2021.	1.0	17
146	Gravesâ€™ disease. Nature Reviews Disease Primers, 2020, 6, 52.	18.1	199
147	Teprotumumab in Thyroid-Associated Ophthalmopathy: Rationale for Therapeutic Insulin-Like Growth Factorâ€™I Receptor Inhibition. Journal of Neuro-Ophthalmology, 2020, 40, 74-83.	0.4	5
148	Ocular conditions and dry eye due to traditional and new forms of smoking: A review. Contact Lens and Anterior Eye, 2020, 43, 277-284.	0.8	16
149	Teprotumumab for the Treatment of Active Thyroid Eye Disease. New England Journal of Medicine, 2020, 382, 341-352.	13.9	375
150	Graves' disease: Clinical manifestations, immune pathogenesis (cytokines and chemokines) and therapy. Best Practice and Research in Clinical Endocrinology and Metabolism, 2020, 34, 101388.	2.2	72
151	Rituximab in Ocular Adnexal Lymphoma and Orbital Inflammatory Disease. International Ophthalmology Clinics, 2020, 60, 63-75.	0.3	1
152	Dysthyroid optic neuropathy: evaluation and management. Journal of Endocrinological Investigation, 2021, 44, 421-429.	1.8	66
153	Treatment of corticosteroid-resistant thyroid eye disease with subcutaneous tocilizumab. Canadian Journal of Ophthalmology, 2021, 56, 66-70.	0.4	12
154	Tratamiento de la oftalmopatÃa de Graves. Medicina ClÃnica, 2021, 156, 180-186.	0.3	8

#	ARTICLE	IF	CITATIONS
155	Efficacy Profile and Safety of Very Low-Dose Rituximab in Patients with Graves' Orbitopathy. <i>Thyroid</i> , 2021, 31, 821-828.	2.4	24
157	Quantification of Global Ocular Motility Impairment in Graves' Orbitopathy by Measuring Eye Muscle Ductions. <i>Thyroid</i> , 2021, 31, 280-287.	2.4	5
159	A pilot study on the use of prednisolone-encapsulated liposomes for the treatment of moderate-to-severe Graves' orbitopathy with reduced systemic steroid exposure. <i>Acta Ophthalmologica</i> , 2021, 99, 797-804.	0.6	4
160	Thyroid eye disease: Redefining its management—A review. <i>Clinical and Experimental Ophthalmology</i> , 2021, 49, 203-211.	1.3	10
161	Diagnostic Approach to the Patient with Proptosis. , 2021, , 545-610.		3
162	Glucocorticoids for Thyroid Eye Disease. <i>International Ophthalmology Clinics</i> , 2021, 61, 63-78.	0.3	3
163	The role of oxidative stress in the pathogenesis of Graves' orbitopathy. <i>Postepy Higieny I Medycyny Doswiadczonej</i> , 2021, 75, 1-10.	0.1	0
164	Improvement Of Graves' Ophthalmopathy After Administration Of The Cyclooxygenase-2 Selective Inhibitor Celecoxib: A Case-Report. <i>European Scientific Journal</i> , 2021, 17, .	0.0	0
165	Graves Ophthalmopathy. , 2021, , 261-271.		0
166	Updates on the understanding and management of thyroid eye disease. <i>Therapeutic Advances in Ophthalmology</i> , 2021, 13, 251584142110277.	0.8	19
167	Treatment of Graves' ophthalmopathy. <i>Medicina Clínica (English Edition)</i> , 2021, 156, 180-186.	0.1	1
168	Steroid-Resistant Graves' Orbitopathy Treated with Tocilizumab in Real-World Clinical Practice: A 9-Year Single-Center Experience. <i>Journal of Clinical Medicine</i> , 2021, 10, 706.	1.0	31
169	Intravenous rituximab therapy for active Graves' ophthalmopathy: a meta-analysis. <i>Hormones</i> , 2021, 20, 279-286.	0.9	12
170	Thyroid Eye Disease: Navigating the New Treatment Landscape. <i>Journal of the Endocrine Society</i> , 2021, 5, bvab034.	0.1	14
171	Multidisciplinary approach to orbital decompression. A review. <i>Acta Otorhinolaryngologica Italica</i> , 2021, 41, S90-S101.	0.7	6
172	Treatment of moderate to severe orbitopathy: Current modalities and perspectives. <i>Annales D'Endocrinologie</i> , 2021, 82, 92-98.	0.6	7
173	Teprotumumab. <i>Ophthalmology</i> , 2021, 128, 1627-1651.	2.5	26
174	Cytokines as Targets of Novel Therapies for Graves' Ophthalmopathy. <i>Frontiers in Endocrinology</i> , 2021, 12, 654473.	1.5	24

#	ARTICLE	IF	CITATIONS
175	Graves' orbitopathy: a multidisciplinary approach. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2021, 65, 157-171.	0.4	4
176	Teprotumumab: The Dawn of Therapies in Moderate-to-Severe Thyroid-Associated Ophthalmopathy. Hormone and Metabolic Research, 2021, 53, 211-218.	0.7	1
177	Rola stresu oksydacyjnego w patogenezie orbitopatii Gravesa. Postepy Higieny I Medycyny Doswiadczalnej, 2021, 75, 448-455.	0.1	0
178	Current Management of Thyroid Eye Disease. Current Treatment Options in Neurology, 2021, 23, 1.	0.7	1
179	Wnt signalling inhibits adipogenesis in orbital fibroblasts from patients with Gravesâ€™ orbitopathy. British Journal of Ophthalmology, 2022, 106, 1019-1027.	2.1	6
180	Teprotumumab for patients with active thyroid eye disease: a pooled data analysis, subgroup analyses, and off-treatment follow-up results from two randomised, double-masked, placebo-controlled, multicentre trials. Lancet Diabetes and Endocrinology, the, 2021, 9, 360-372.	5.5	91
181	Gravesâ€™ disease with spontaneous resolution following ocrelizumab in primary progressive multiple sclerosis. Endocrine Regulations, 2021, 55, 169-173.	0.5	2
182	The 2021 European Group on Gravesâ€™ orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Gravesâ€™ orbitopathy. European Journal of Endocrinology, 2021, 185, G43-G67.	1.9	362
183	A Perspective on the Current Role of Teprotumumab in Treatment of Thyroid Eye Disease. Ophthalmology, 2021, 128, 1125-1128.	2.5	8
184	2021 update on thyroid-associated ophthalmopathy. Journal of Endocrinological Investigation, 2022, 45, 235-259.	1.8	44
185	Overview of Graves Ophthalmopathy Literature From 1999 to 2019: Bibliometric Analysis. Interactive Journal of Medical Research, 2021, 10, e24831.	0.6	4
186	Graves's Orbitopathy: Current Concepts for Medical Treatment. Klinische Monatsblätter Fur Augenheilkunde, 2021, 238, 24-32.	0.3	5
187	Medical treatment in thyroid eye disease in 2020. British Journal of Ophthalmology, 2021, 105, 299-305.	2.1	20
188	Circulating Exosomes From Patients With Gravesâ€™ Disease Induce an Inflammatory Immune Response. Endocrinology, 2021, 162, .	1.4	10
189	Will biological agents supplant systemic glucocorticoids as the first-line treatment for thyroid-associated ophthalmopathy?. European Journal of Endocrinology, 2019, 181, D27-D43.	1.9	19
190	The role of cell mediated immunopathogenesis in thyroid-associated ophthalmopathy. International Journal of Ophthalmology, 2019, 12, 1209-1214.	0.5	5
191	Preclinical Models of Gravesâ€™ Disease and Associated Secondary Complications. Current Pharmaceutical Design, 2015, 21, 2414-2421.	0.9	9
192	Current Knowledge on Gravesâ€™ Orbitopathy. Journal of Clinical Medicine, 2021, 10, 16.	1.0	26

#	ARTICLE	IF	CITATIONS
193	Medical management of thyroid eye disease – A paradigm shift. Indian Journal of Ophthalmology, 2020, 68, 1515.	0.5	2
194	Progress in the pathogenesis of thyroid-associated ophthalmopathy and new drug development. Taiwan Journal of Ophthalmology, 2020, 10, 174.	0.3	8
195	Management of Thyrotoxicosis in Children and Adolescents: A Turkish Multi-center Experience. JCRPE Journal of Clinical Research in Pediatric Endocrinology, 2019, 11, 164-172.	0.4	8
196	Immunogenicity of Rituximab, Trastuzumab, and Bevacizumab Monoclonal Antibodies in Patients with Malignant Diseases. International Journal of Cancer Management, 2018, In Press, .	0.2	3
197	Disulfiram Exerts Antiadipogenic, Anti-Inflammatory, and Antifibrotic Therapeutic Effects in an In Vitro Model of Graves' Orbitopathy. Thyroid, 2022, 32, 294-305.	2.4	7
198	Adjuvant Rituximab – Exploratory Trial in Young People With Graves Disease. Journal of Clinical Endocrinology and Metabolism, 2022, 107, 743-754.	1.8	15
200	Graves – Ophthalmopathy. Endocrinology, 2016, , 1-39.	0.1	0
201	Treatment of Graves – Disease. Endocrinology, 2016, , 1-24.	0.1	0
202	Sight Threatening Thyroid Eye Disease Complicating Hashimoto – Thyroiditis. Endocrinology & Metabolic Syndrome: Current Research, 2017, 06, .	0.3	0
203	Rituximab therapy in steroid resistant thyroid associated ophthalmopathy. Case Reports International, 2017, 6, 17.	0.0	0
204	Effect of Patients – Endocrine Status on Effectiveness of Treatment with Rituximab: State of the Art. Klinicheskaya Onkogematologiya/Clinical Oncohematology, 2017, 10, 187-190.	0.1	0
205	Treatment of Graves' Ophthalmopathy. International Journal of Thyroidology, 2019, 12, 91.	0.1	0
208	Chemokine Expression during Adipogenesis and Inflammation in Orbital Fibroblasts from Patients with Graves' Orbitopathy. Korean Journal of Ophthalmology: KJO, 2020, 34, 192-202.	0.5	3
210	Pathogenesis and Medical Management of Thyroid Eye Disease. , 2021, , 983-999.		0
211	Precision Medicine in Graves – Disease and Ophthalmopathy. Frontiers in Pharmacology, 2021, 12, 754386.	1.6	13
212	Application of Data Science Approaches to Investigate Autoimmune Thyroid Disease in Precision Medicine. , 0, , .		0
213	Efficacy and Safety of Teprotumumab in Thyroid Eye Disease. Therapeutics and Clinical Risk Management, 2021, Volume 17, 1219-1230.	0.9	10
215	Graves – Orbitopathy and Dermopathy. , 2022, , 506-518.		0

#	ARTICLE	IF	CITATIONS
217	Thyroid eye disease: From pathogenesis to targeted therapies. <i>Taiwan Journal of Ophthalmology</i> , 2022, 12, 3.	0.3	9
218	Therapy With Different Dose Regimens of Rituximab in Patients With Active Moderate-To-Severe Gravesâ€™ Orbitopathy. <i>Frontiers in Endocrinology</i> , 2021, 12, 790246.	1.5	10
220	Management of eyelid retraction related to thyroid eye disease. <i>Taiwan Journal of Ophthalmology</i> , 2022, 12, 12.	0.3	6
221	Orbitopathie basedowienne. , 2022, , 160-179.		0
222	Proptosis and Diplopia Response With Teprotumumab and Placebo vs the Recommended Treatment Regimen With Intravenous Methylprednisolone in Moderate to Severe Thyroid Eye Disease. <i>JAMA Ophthalmology</i> , 2022, 140, 328.	1.4	29
224	A Paradigm Shift in the Management of Thyroid Eye Disease How Teprotumumab Has Changed the Therapeutic Interface. <i>Journal of Neuro-Ophthalmology</i> , 2022, 42, 26-34.	0.4	1
225	Long-term outcomes in corticosteroidâ€‘refractory Graves' orbitopathy treated with tocilizumab. <i>Clinical Endocrinology</i> , 2022, 97, 363-370.	1.2	7
226	Comparative effectiveness of different treatment modalities for active, moderateâ€‘toâ€‘severe Graves' orbitopathy: a systematic review and network metaâ€‘analysis. <i>Acta Ophthalmologica</i> , 2022, 100, .	0.6	3
227	Pediatric Gravesâ€™ orbitopathy: a multicentre study. <i>Acta Ophthalmologica</i> , 2022, 100, .	0.6	5
232	Drug safety in thyroid eye disease â€‘ a systematic review. <i>Expert Opinion on Drug Safety</i> , 2022, , .	1.0	1
233	2022â€‘Update on Clinical Management of Graves Disease and Thyroid Eye Disease. <i>Endocrinology and Metabolism Clinics of North America</i> , 2022, 51, 287-304.	1.2	23
234	Dihydroartemisinin Exerts Antifibrotic and Anti-Inflammatory Effects in Gravesâ€™ Ophthalmopathy by Targeting Orbital Fibroblasts. <i>Frontiers in Endocrinology</i> , 2022, 13, .	1.5	3
235	Current concepts regarding Gravesâ€™ orbitopathy. <i>Journal of Internal Medicine</i> , 2022, 292, 692-716.	2.7	37
236	Advances in the Treatment of Thyroid Eye Disease Associated Extraocular Muscle Myopathy and Optic Neuropathy. <i>Current Neurology and Neuroscience Reports</i> , 0, , .	2.0	1
237	Rituximab for thyroid-associated ophthalmopathy. <i>The Cochrane Library</i> , 2022, 2022, .	1.5	2
238	Adjuvant Rituximab May Increase Remission in Young Patients with Graves' Disease. <i>Clinical Thyroidology</i> , 2022, 34, 243-245.	0.0	0
239	Update on thyroid eye disease: Regional variations in prevalence, diagnosis, and management. <i>Indian Journal of Ophthalmology</i> , 2022, 70, 2335.	0.5	6
240	Teprotumumab. <i>Advances in Ophthalmology and Optometry</i> , 2022, , .	0.3	0

#	ARTICLE	IF	CITATIONS
241	How can we prevent disease relapse in Gravesâ€™ orbitopathy after immunosuppressive treatment?. Expert Review of Endocrinology and Metabolism, 2022, 17, 269-274.	1.2	1
242	Future Projections in Thyroid Eye Disease. Journal of Clinical Endocrinology and Metabolism, 2022, 107, S47-S56.	1.8	16
243	Measuring Health-Related Quality of Life in Thyroid Eye Disease. Journal of Clinical Endocrinology and Metabolism, 2022, 107, S27-S35.	1.8	2
244	Teprotumumab and the Evolving Therapeutic Landscape in Thyroid Eye Disease. Journal of Clinical Endocrinology and Metabolism, 2022, 107, S36-S46.	1.8	7
245	Understanding Pathogenesis Intersects With Effective Treatment for Thyroid Eye Disease. Journal of Clinical Endocrinology and Metabolism, 2022, 107, S13-S26.	1.8	5
246	Single-cell RNA sequencing depicts the local cell landscape in thyroid-associated ophthalmopathy. Cell Reports Medicine, 2022, 3, 100699.	3.3	11
247	Recent advances in graves ophthalmopathy medical therapy: a comprehensive literature review. International Ophthalmology, 2023, 43, 1437-1449.	0.6	1
248	Rituximab in the treatment of Gravesâ€™ orbitopathy: latest updates and perspectives. Endocrine Connections, 2022, 11, .	0.8	4
249	Long-term management of Graves disease: a narrative review. , 2023, 40, 12-22.		4
250	Metabolic adverse events associated with systemic corticosteroid therapyâ€™ a systematic review and meta-analysis. BMJ Open, 2022, 12, e061476.	0.8	2
251	Management of Thyroid Eye Disease: A Consensus Statement by the American Thyroid Association and the European Thyroid Association. Thyroid, 2022, 32, 1439-1470.	2.4	36
252	Thyroid Eye Disease. Life, 2022, 12, 2084.	1.1	4
253	Management of thyroid eye disease: a Consensus Statement by the American Thyroid Association and the European Thyroid Association. European Thyroid Journal, 2022, 11, .	1.2	19
254	Review of an Anti-CD20 Monoclonal Antibody for the Treatment of Autoimmune Diseases of the Skin. American Journal of Clinical Dermatology, 0, , .	3.3	4
255	Non-thionamide antithyroid drug options in Gravesâ€™ hyperthyroidism. Expert Review of Endocrinology and Metabolism, 2023, 18, 67-79.	1.2	3
256	A rare case of severe bilateral Gravesâ€™ orbitopathy involving an anophthalmic socket. Endocrinology, Diabetes and Metabolism Case Reports, 2023, 2023, .	0.2	0
257	Ophthalmological manifestations of systemic autoimmune diseases. , 2023, , 183-214.		0
258	Observation study of using a small dose of rituximab treatment for thyroid-associated ophthalmopathy in seven Chinese patients: One pilot study. Frontiers in Endocrinology, 0, 13, .	1.5	1

#	ARTICLE	IF	CITATIONS
259	Teprotumumab for the treatment of thyroid eye disease. <i>Expert Opinion on Biological Therapy</i> , 2023, 23, 123-131.	1.4	1
260	A review of TSHR- and IGF-1R-related pathogenesis and treatment of Gravesâ€™ orbitopathy. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	4
261	Monoclonal Antibodies for the Treatment of Graves Orbitopathy: Precision Medicine?. <i>Ophthalmic Plastic and Reconstructive Surgery</i> , 2023, 39, 307-315.	0.4	1
262	Heterogeneity of antibody-secreting cells infiltrating autoimmune tissues. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	0
263	Dysthyroid optic neuropathy: emerging treatment strategies. <i>Journal of Endocrinological Investigation</i> , 2023, 46, 1305-1316.	1.8	5
265	Medical Management of Thyroid Eye Disease. <i>International Ophthalmology Clinics</i> , 2023, 63, 81-89.	0.3	0
266	Inter-observer Variability of Clinical Activity Score: Assessments in Patients With Thyroid Eye Disease. <i>American Journal of Ophthalmology</i> , 2023, 252, 94-100.	1.7	1
267	Prostaglandin F2Î± Regulates Adipogenesis by Modulating Extracellular Signal-Regulated Kinase Signaling in Gravesâ€™ Ophthalmopathy. <i>International Journal of Molecular Sciences</i> , 2023, 24, 7012.	1.8	0
280	Understanding the clinical and molecular basis of thyroid orbitopathy: a review of recent evidence. <i>Hormones</i> , 2024, 23, 25-34.	0.9	1
287	Medical Management of Gravesâ€™ Orbitopathy. , 2023, , 287-293.		0